SILK Silk Road Medical Inc

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 14A
(Rule 14A-101)

 

PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Filed by the Registrant þ

Filed by a Party other than the Registrant ¨

 

Check the appropriate box:

¨ Preliminary Proxy Statement

¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨ Definitive Proxy Statement

¨ Definitive Additional Materials

þ Soliciting Material under § 240.14a-12

SILK ROAD MEDICAL, INC.
(Name of Registrant as Specified in its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

þ No fee required

¨ Fee paid previously with preliminary materials

¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

All Hands Town Hall Message – calendar invite

 

Following the message from Chas this morning, please join him and leaders from Boston Scientific’s Peripheral Interventions business for a town hall.

 

Employees in Plymouth and Sunnyvale can join us in the respective lunchrooms. Employees not in either location can join via the Zoom link below.

 

Alison

 

SOCIAL MEDIA

 

LinkedIn Post

 

Silk Road Medical announced it has entered into a definitive merger agreement to be acquired by Boston Scientific. The transaction has been unanimously approved by the Silk Road’s Board of Directors.

 

The transaction is expected to be completed in the second half of 2024, subject to the satisfaction of customary closing conditions, including approval by Silk Road’s stockholders and applicable regulatory approval. Silk Road released the announcement on June 18, 2024, which contains important information about the transaction and should be read in its entirety.

 

LINK TO PRESS RELEASE

 

Twitter Post

 

Silk Road Medical announced it has entered into an agreement to be acquired by Boston Scientific Corporation. This transaction has been unanimously approved by Silk Road’s Board and is subject to customary closing conditions.

 

Read Silk Road’s announcement, which contains important information: LINK TO PRESS RELEASE

 

 

---